BioTrove has announced the expansion of its relationship with Sirtris Pharmaceuticals. As part of the ongoing relationship, BioTrove will use its proprietary RapidFire™ Lead Discovery service for assay development and high throughput screening on an undisclosed number of Sirtris targets.
RapidFire™ Lead Discovery uses high throughput mass spectrometry to perform label-free assays using native biological substrates enabling the screening of intractable targets.
“The expansion of our relationship with Sirtris provides further validation of the value of RapidFire™ Lead Discovery,” said Alan Carter, vice president of business development and field operations.
“Our expanding customer base continues to find new leads and information on valuable targets when compared to classical HTS methods.”